What is Cellphire?
Cellphire Therapeutics is dedicated to saving lives by developing innovative platelet therapeutics aimed at addressing controllable hemorrhage, a leading cause of preventable death. Their products, including the freeze-dried platelet-derived hemostat FPH and Cryopreserved Platelets CPP, are currently in Phase 2 clinical studies and aim to improve hemostatic efficacy for military and civilian patients. The company focuses on ensuring that effective therapies are available to clinicians, particularly in critical situations such as trauma and surgery. With a vision that no one should die from controllable hemorrhage, Cellphire is committed to revolutionizing bleeding treatment through advanced cellular therapies.
How much funding has Cellphire raised?
Cellphire has raised a total of $20.6M across 5 funding rounds:
Debt
$1M
Other Financing Round
$1.3M
Other Financing Round
$3M
Debt
$350K
Series A
$15M
Debt (2014): $1M, investors not publicly disclosed
Other Financing Round (2016): $1.3M led by Maryland Department of Commerce
Other Financing Round (2017): $3M supported by Maryland Department of Commerce
Debt (2020): $350K featuring PPP
Series A (2021): $15M backed by Simcah Management
Key Investors in Cellphire
Simcah Management
Simcah Management is an investor that participated in Cellphire's Series A funding round. Further details on their investment focus are not publicly available.
Maryland Department of Commerce
The Maryland Department of Commerce has provided financing to Cellphire on multiple occasions, indicating a commitment to supporting local biotechnology and life sciences companies within the state.
PPP
Public-Private Partnership
What's next for Cellphire?
The recent major strategic investment of $15M positions Cellphire to accelerate the clinical development and potential commercialization of its novel platelet-based hemostatic agents. This capital infusion is expected to fuel further progress in their Phase 2 clinical studies for FPH and CPP, bringing them closer to addressing a critical unmet need in trauma care. The company's focus on improving hemostatic efficacy for both military and civilian applications suggests a strategic expansion into diverse markets. Future endeavors will likely involve navigating regulatory pathways and scaling manufacturing capabilities to meet anticipated demand for these life-saving therapies.
See full Cellphire company page
